Published in Neuropsychiatr Dis Treat on June 01, 2005
Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet (1993) 7.97
Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell (1998) 6.24
Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet (1998) 4.27
An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8) Nat Genet (1999) 4.15
Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet (1997) 4.12
Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell (1998) 4.07
Spinocerebellar ataxia type 5 in a family descended from the grandparents of President Lincoln maps to chromosome 11. Nat Genet (1994) 3.89
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell (1995) 2.96
Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet (2000) 2.60
Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron (2003) 2.39
Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron (2001) 2.29
The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet (1993) 2.18
Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet (2000) 2.17
Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet (2001) 2.13
Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet (1994) 2.13
The non-coding RNAs as riboregulators. Nucleic Acids Res (2001) 2.11
Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet (1999) 1.95
Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet (2004) 1.85
Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12. Nat Genet (1999) 1.74
Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals. Nat Genet (1995) 1.70
A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet (1999) 1.69
Spinocerebellar ataxia and HLA linkage: risk prediction by HLA typing. N Engl J Med (1977) 1.67
Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet (2000) 1.67
The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature (1997) 1.61
The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila. Curr Biol (2004) 1.51
Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci U S A (2004) 1.47
The SCA8 transcript is an antisense RNA to a brain-specific transcript encoding a novel actin-binding protein (KLHL1). Hum Mol Genet (2000) 1.43
Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology (2002) 1.40
Missense mutations in the regulatory domain of PKC gamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet (2003) 1.36
Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol (1997) 1.29
Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol (2003) 1.29
Trinucleotide repeats in 202 families with ataxia: a small expanded (CAG)n allele at the SCA17 locus. Arch Neurol (2002) 1.26
SCA8 repeat expansion: large CTA/CTG repeat alleles are more common in ataxic patients, including those with SCA6. Am J Hum Genet (2003) 1.24
Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet (2003) 1.22
Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem (2002) 1.21
A Drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. Genetics (2002) 1.19
Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet (2000) 1.17
SCA8 CTG repeat: en masse contractions in sperm and intergenerational sequence changes may play a role in reduced penetrance. Hum Mol Genet (2000) 1.17
CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms. Hum Mol Genet (2001) 1.16
Increased trinucleotide repeat instability with advanced maternal age. Hum Mol Genet (1997) 1.15
Genomic context drives SCA7 CAG repeat instability, while expressed SCA7 cDNAs are intergenerationally and somatically stable in transgenic mice. Hum Mol Genet (2003) 1.14
Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. Hum Mol Genet (1999) 1.12
Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology (1972) 1.07
Mapping of a new autosomal dominant spinocerebellar ataxia to chromosome 22. Am J Hum Genet (1999) 1.07
Intergenerational instability and marked anticipation in SCA-17. Neurology (2003) 1.06
Expanded CAG repeats activate the DNA damage checkpoint pathway. Mol Cell (2004) 1.05
CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. Hum Mol Genet (2000) 0.97
Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.1. Am J Hum Genet (1997) 0.96
Anticipation in spinocerebellar ataxia type 2. Nat Genet (1993) 0.94
The gene for autosomal dominant spinocerebellar ataxia (SCA1) maps centromeric to D6S89 and shows no recombination, in nine large kindreds, with a dinucleotide repeat at the AM10 locus. Am J Hum Genet (1993) 0.94
SCA8 repeat expansion coexists with SCA1--not only with SCA6. Am J Hum Genet (2003) 0.93
Spinocerebellar ataxia type 6 and episodic ataxia type 2: differences and similarities between two allelic disorders. Cytogenet Genome Res (2003) 0.92
Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications for the molecular mechanisms of the instability of the CAG repeat. Hum Mol Genet (1996) 0.91
Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix. Hum Mol Genet (1999) 0.90
Rapid cloning of expanded trinucleotide repeat sequences from genomic DNA. Nat Genet (1998) 0.90
Genetic linkage studies of Machado-Joseph disease with chromosome 14q STRPs in 16 Portuguese-Azorean kindreds. Genomics (1994) 0.89
Dynamics of CAG repeat loci revealed by the analysis of their variability. Hum Mutat (2003) 0.89
Analysis of spinocerebellar ataxia types 1, 2, 3, and 6, dentatorubral-pallidoluysian atrophy, and Friedreich's ataxia genes in spinocerebellar ataxia patients in the UK. J Med Genet (1997) 0.86
Polyglutamine-expanded ataxin-1 recruits Cu/Zn-superoxide dismutase into the nucleus of HeLa cells. Biochem Biophys Res Commun (2003) 0.84
Molecular analysis of Spinocerebellar ataxias in Koreans: frequencies and reference ranges of SCA1, SCA2, SCA3, SCA6, and SCA7. Mol Cells (2001) 0.83
A new dominant spinocerebellar ataxia linked to chromosome 19q13.4-qter. Arch Neurol (2002) 0.82
Autosomal dominant spinocerebellar ataxia (SCA) in a Siberian founder population: assignment to the SCA1 locus. Exp Neurol (1994) 0.81
A novel locus for dominant cerebellar ataxia (SCA14) maps to a 10.2-cM interval flanked by D19S206 and D19S605 on chromosome 19q13.4-qter. Ann Neurol (2000) 0.80
Frequency analysis of autosomal dominant cerebellar ataxias in Japanese patients and clinical characterization of spinocerebellar ataxia type 6. Clin Genet (1998) 0.78
Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci (2007) 1.56
Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia (2013) 1.55
Favorable early outcome of carotid artery stenting without protection devices. Stroke (2004) 1.41
Tumour necrosis factor alpha gene (TNF-alpha) -376 polymorphism in Hungarian patients with primary progressive multiple sclerosis. J Neuroimmunol (2009) 1.40
The kynurenine system and immunoregulation. J Neural Transm (Vienna) (2011) 1.38
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm (Vienna) (2010) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res (2005) 0.96
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav (2009) 0.94
l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology (2009) 0.92
Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS J (2008) 0.92
Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci Lett (2007) 0.90
Dementia, stroke and migraine--some common pathological mechanisms. J Neurol Sci (2010) 0.90
Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene-related peptide via activation of extracellular signal-regulated protein kinase 1/2. Cephalalgia (2010) 0.89
Kynurenate derivative attenuates the nitroglycerin-induced CamKIIα and CGRP expression changes. Headache (2009) 0.88
Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.87
Kynurenines, neurodegeneration and Alzheimer's disease. J Cell Mol Med (2010) 0.87
Hippocampal (CA1) activities in Wistar rats from different vendors. Fundamental differences in acute ischemia. J Neurosci Methods (2006) 0.87
Complex hallucinations following occipital lobe damage. Eur J Neurol (2002) 0.86
The Janus-face kynurenic acid. J Neural Transm (Vienna) (2008) 0.85
Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis (2008) 0.85
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. J Neuroimmunol (2006) 0.85
White matter microstructural alterations in migraine: a diffusion-weighted MRI study. Pain (2012) 0.85
Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol (2007) 0.84
[The carrier model of neurology in Hungary: a proposal for the solution until 2020]. Ideggyogy Sz (2011) 0.84
The effects of reward and punishment contingencies on decision-making in multiple sclerosis. J Int Neuropsychol Soc (2006) 0.84
Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci (2012) 0.83
Oxaloacetate restores the long-term potentiation impaired in rat hippocampus CA1 region by 2-vessel occlusion. Eur J Pharmacol (2008) 0.83
Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion. Exp Neurol (2004) 0.83
Cortical and subcortical atrophy in Alzheimer disease: parallel atrophy of thalamus and hippocampus. Alzheimer Dis Assoc Disord (2014) 0.83
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med (2011) 0.83
Evans Blue fluorescence permits the rapid visualization of non-intact cells in the perilesional rim of cold-injured rat brain. Acta Neurobiol Exp (Wars) (2007) 0.82
Gray matter is targeted in first-attack multiple sclerosis. PLoS One (2013) 0.82
Novel sequence variants of the alpha-galactosidase A gene in patients with Fabry disease. Mol Genet Metab (2008) 0.82
[VALIDATION OF THE HUNGARIAN MDS-UPDRS: WHY DO WE NEED A NEW PARKINSON SCALE?]. Ideggyogy Sz (2014) 0.82
A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study. J Neural Transm (Vienna) (2009) 0.81
Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur J Pharmacol (2011) 0.81
Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. J Alzheimers Dis (2011) 0.81
Effects of blood glutamate scavenging on cortical evoked potentials. Cell Mol Neurobiol (2010) 0.81
Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosis. Int J Mol Sci (2012) 0.81
The pattern of diffusion parameter changes in Alzheimer's disease, identified by means of linked independent component analysis. J Alzheimers Dis (2013) 0.81
Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex. J Neural Transm (Vienna) (2014) 0.81
Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability. Drug Des Devel Ther (2013) 0.80
Modifications on the carboxylic function of kynurenic acid. J Neural Transm (Vienna) (2011) 0.80
Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol (2006) 0.80
Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system. Peptides (2012) 0.80
Kynurenines and intestinal neurotransmission: the role of N-methyl-D-aspartate receptors. J Neural Transm (Vienna) (2011) 0.80
Kynurenines in Parkinson's disease: therapeutic perspectives. J Neural Transm (Vienna) (2011) 0.80
Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur J Pharmacol (2005) 0.80
Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate. Life Sci (2008) 0.79
Somatostatin and cognitive function in neurodegenerative disorders. Mini Rev Med Chem (2013) 0.79
Current medical aspects of pantethine. Ideggyogy Sz (2009) 0.79
N-methyl-D-aspartate receptor antagonist therapy suppresses colon motility and inflammatory activation six days after the onset of experimental colitis in rats. Eur J Pharmacol (2012) 0.79
The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors. J Neural Transm (Vienna) (2013) 0.79
Kynurenines and headache. J Neural Transm (Vienna) (2011) 0.79
[Endangered future: education and replacement of specialists in neurology--a survey in Hungary, 2010]. Ideggyogy Sz (2010) 0.78
Neurology in Hungary: past, present, and future. Neurology (2013) 0.78
Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients. Neuroimmunomodulation (2005) 0.78
A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. Biochem Biophys Res Commun (2011) 0.78
Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives. Curr Neuropharmacol (2011) 0.78
Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.78
Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient. Chin Med J (Engl) (2006) 0.78
Behavioural studies with a newly developed neuroprotective KYNA-amide. J Neural Transm (Vienna) (2011) 0.78
Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv Exp Med Biol (2004) 0.78
[Botulinum neurotoxin--a therapy in migraine]. Ideggyogy Sz (2012) 0.78
Effect of probenecid on the pain-related behaviour and morphological markers in orofacial formalin test of the rat. CNS Neurol Disord Drug Targets (2015) 0.77
Target identification for stereotactic thalamotomy using diffusion tractography. PLoS One (2012) 0.77
Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain. Exp Neurol (2002) 0.77
Safinamide for the treatment of Parkinson's disease. Expert Opin Investig Drugs (2014) 0.77
Grey matter atrophy in patients suffering from multiple sclerosis. Ideggyogy Sz (2014) 0.77
The effect of sleep deprivation on median nerve somatosensory evoked potentials. Neurosci Lett (2005) 0.77
White matter disintegration in cluster headache. J Headache Pain (2013) 0.77
Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits. J Cardiovasc Pharmacol (2003) 0.77
Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. Cereb Cortex (2002) 0.77
Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Neuropharmacology (2015) 0.77
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. Ideggyogy Sz (2008) 0.77
Evaluation of c-Fos immunoreactivity in the rat brainstem nuclei relevant in migraine pathogenesis after electrical stimulation of the trigeminal ganglion. Neurol Sci (2013) 0.77
[Mechanism of cough syncope]. Orv Hetil (2004) 0.77
Calcitonin gene-related peptide levels in saliva of patients with burning mouth syndrome. J Oral Pathol Med (2009) 0.77
Dissociation between attentional set shifting and habit learning: a longitudinal case study. Neurocase (2002) 0.77
[The mechanism of peripheral and central sensitization in migraine. A literature review]. Neuropsychopharmacol Hung (2009) 0.77
Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol (2011) 0.77
Effects of 3-aminopyridine-induced seizures on platelet eicosanoid synthesis. Pharmacol Rep (2008) 0.76
Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up. J Interferon Cytokine Res (2006) 0.76
Validation of the Fatigue Impact Scale in Hungarian patients with multiple sclerosis. Qual Life Res (2010) 0.76
[Complementary therapies--based on the principles of evidence-based medicine. Position statement of the Medical Sciences Section of the Hungarian Academy of Sciences]. Orv Hetil (2011) 0.76
A genome-wide screen for association in Hungarian multiple sclerosis. J Neuroimmunol (2003) 0.76
Molecular plasticity of primary nociceptive neurons: relations of the NGF-c-jun system to neurotomy and chronic pain. Ann Anat (2003) 0.76
RAGE gene polymorphisms in patients with multiple sclerosis. J Mol Neurosci (2009) 0.76
A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study : special issue related to kynurenine. J Neural Transm (Vienna) (2012) 0.76
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. J Neural Transm (Vienna) (2012) 0.76
Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. Expert Opin Drug Metab Toxicol (2014) 0.76
Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. J Pharm Biomed Anal (2011) 0.76
Electrophysiological correlates of visual categorization: evidence for cognitive dysfunctions in early Parkinson's disease. Brain Res Cogn Brain Res (2002) 0.76
Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol Biochem Behav (2004) 0.75
Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part II: Potential causes and laboratory tests. Ideggyogy Sz (2013) 0.75
[Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary]. Ideggyogy Sz (2014) 0.75
[Nature Reviews Drug Discovery: editorial article of neuroscientists from Szeged about kynurenine (IF: 33.078)]. Ideggyogy Sz (2014) 0.75
[Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders]. Ideggyogy Sz (2003) 0.75
Kynurenines and other novel therapeutic strategies in the treatment of dementia. Ther Adv Neurol Disord (2013) 0.75